An option for your patients who require an LDL-C reduction of >60%1
A device you’ll recognise with one step less2,3
Only PCSK9i with once-monthly single injection in a pre-filled pen1
The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.
If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.
For full instructions on use refer to the Patient information Leaflet
CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.